Effectiveness of Osimertinib in Patients with Lung Adenocarcinoma in Clinical Practice—The Expanded Drug Access Program in Poland
Abstract
Share and Cite
Knetki-Wróblewska, M.; Kowalski, D.M.; Czyżewicz, G.; Bryl, M.; Wrona, A.; Dziadziuszko, R.; Kieszko, R.; Milanowski, J.; Świniuch, D.; Ramlau, R.; et al. Effectiveness of Osimertinib in Patients with Lung Adenocarcinoma in Clinical Practice—The Expanded Drug Access Program in Poland. Adv. Respir. Med. 2020, 88, 189-196. https://doi.org/10.5603/ARM.2020.0130
Knetki-Wróblewska M, Kowalski DM, Czyżewicz G, Bryl M, Wrona A, Dziadziuszko R, Kieszko R, Milanowski J, Świniuch D, Ramlau R, et al. Effectiveness of Osimertinib in Patients with Lung Adenocarcinoma in Clinical Practice—The Expanded Drug Access Program in Poland. Advances in Respiratory Medicine. 2020; 88(3):189-196. https://doi.org/10.5603/ARM.2020.0130
Chicago/Turabian StyleKnetki-Wróblewska, Magdalena, Dariusz M. Kowalski, Grzegorz Czyżewicz, Maciej Bryl, Anna Wrona, Rafał Dziadziuszko, Robert Kieszko, Janusz Milanowski, Daria Świniuch, Rodryg Ramlau, and et al. 2020. "Effectiveness of Osimertinib in Patients with Lung Adenocarcinoma in Clinical Practice—The Expanded Drug Access Program in Poland" Advances in Respiratory Medicine 88, no. 3: 189-196. https://doi.org/10.5603/ARM.2020.0130